Pathology & Oncology Research: review time and acceptance speed
ISSN 1219-4956 · ISSN 1532-2807 · Springer Science+Business Media · Medicine
Half of the articles Pathology & Oncology Research accepted in 2024 were accepted within 81 days of submission (n = 66); the middle half took 52–120 days.
Accepted articles only · dates deposited by the publisher in PubMed · data as of Sep 15, 2026
How long does Pathology & Oncology Research take to accept a paper?
| Year | Articles (n) | 25th pct | Median | 75th pct | 90th pct | Accepted <14 days | Have a revised date |
|---|---|---|---|---|---|---|---|
| 2024 | 66 | 52 | 81 | 120 | — | 0.0% | 0% |
| 2023 | 93 | 65 | 88 | 125 | — | 0.0% | 0% |
| 2022 | 139 | 74 | 106 | 134 | — | 0.0% | 0% |
| 2021 | 165 | 88 | 123 | 162 | — | 0.0% | 0% |
| 2020 | 75 | 29 | 125 | 203 | — | 8.0% | 11% |
- 2026: not shown yet — a year is reported once late-indexed articles have arrived (at least 180 days after it ends).
Distribution in 2024
Show as a table
| Days | Articles | Share |
|---|---|---|
| 0–29 | 2 | 3.0% |
| 30–59 | 17 | 25.8% |
| 60–89 | 19 | 28.8% |
| 90–119 | 10 | 15.2% |
| 120–149 | 12 | 18.2% |
| 150–179 | 3 | 4.5% |
| 180–209 | 1 | 1.5% |
| 210–239 | 1 | 1.5% |
| 240–269 | 0 | 0.0% |
| 270–299 | 0 | 0.0% |
| 300–329 | 0 | 0.0% |
| 330–359 | 1 | 1.5% |
| 360+ | 0 | 0.0% |
From acceptance to online publication
After acceptance, half of the 2024 articles appeared online within 15 days (middle half 13–19 days, n = 66).
From submission to online publication, the median was 95 days (middle half 71–137 days, n = 66).
Read these numbers carefully
- These times describe articles the journal accepted. Rejected manuscripts never appear in public data, so they cannot tell you how long a rejection takes.
- Dates are the ones the publisher deposited with PubMed. Some publishers record the date a revised manuscript arrived as the submission date, which makes review look faster.
- Invited articles and special issues can move faster than regular submissions.
Open access status and publishing fees
Open access (listed in DOAJ). Listed APC: $2,500 (DOAJ).
OpenAPC has fewer than 5 reported payments for this journal in 2023–2025, so no typical amount is shown.
Many journals waive or reduce fees for authors from eligible countries or institutions with publishing agreements — check with the journal and your library.
Integrity and indexing signals
Facts from public records, shown without judgement. See the methodology for why each can be worth a closer look.
| Listed in DOAJ | Yes (DOAJ record) |
|---|---|
| Articles indexed for MEDLINE in 2024 | Yes |
| Retractions | 5 retracted articles among 509 added to PubMed in 2021–2025 (9.82 per 1,000), per the Retraction Watch Database. |
| Accepted within 14 days of submission | 0.0% of 2024 articles |
| Publication volume | 70 articles added to PubMed in 2024 (-25% vs 2023). |
Topics and scope
- Cancer-related molecular mechanisms research (8% of indexed topics)
- Cancer Genomics and Diagnostics (6% of indexed topics)
- RNA modifications and cancer (6% of indexed topics)
- Genetic factors in colorectal cancer (5% of indexed topics)
- Sarcoma Diagnosis and Treatment (5% of indexed topics)
- Cancer-related Molecular Pathways (5% of indexed topics)
Medicine journalsBiochemistry, Genetics and Molecular Biology journalsCancer Research journalsOncology journals
Similar journals — faster or cheaper, side by side
Journals publishing on the most similar topics (OpenAlex), ordered by similarity. Only 2024 figures are compared with the 2024 median of Pathology & Oncology Research, 81 days.
| Paid APC median | DOAJ | MEDLINE | |||
|---|---|---|---|---|---|
| Oncology Letters | 112 (2024, n = 585) | — | — | No | No |
| Journal of Cancer | 77 (2024, n = 499) | ≈$2,850 | $2,407 (5 payments) | Yes | No |
| Neoplasma | 125 (2024, n = 51) | — | — | No | Yes |
| Molecular Oncology | 167 (2024, n = 205) | $4,730 | $3,784 (6 payments) | Yes | Yes |
| Medical Oncology | 50 (2024, n = 243) | ≈$4,290 | — | No | Yes |
| Cancer Science | 113 (2024, n = 315) | $2,600 | — | Yes | Yes |
| Oncology Reports | 102 (2024, n = 107) | — | — | No | Yes |
| Pathology - Research and Practice | 75 (2024, n = 592) | ≈$2,780 | — | No | Yes |
| Cancer Genomics & Proteomics | 47 (2024, n = 62) | — | $1,364 (6 payments) | No | Yes |
No journals match these filters.
Frequently asked questions
How long does Pathology & Oncology Research take to accept a paper?
Half of the articles Pathology & Oncology Research accepted in 2024 were accepted within 81 days of submission (n = 66); the middle half took 52–120 days. Based on dates in PubMed for accepted articles only.
How long after acceptance are Pathology & Oncology Research articles published online?
Half of the articles accepted in 2024 appeared online within 15 days of acceptance (n = 66).
Does Pathology & Oncology Research charge an article processing charge (APC)?
Listed APC: $2,500 (DOAJ).
Sources and method
Journal identity: ISSN-L 1219-4956; NLM ID 9706087; OpenAlex record. Speed figures use 66 articles accepted in 2024 with valid dates; excluded records for that year: none.
Spotted a problem with this journal's data, or are you the publisher? Report a correction or email rafiq@gradsummit.com. Verified errors are corrected within five business days.
Get the free Journal Submission Go/No-Go Checklist
The pre-submission checks from Write and Publish a Scientific Paper: journal fit, formatting, cover letter and reviewer suggestions. We’ll email you the download link.
Data sources. Submission, acceptance and publication dates: Courtesy of the U.S. National Library of Medicine (PubMed, entries through Sep 15, 2026). NLM does not endorse Journal Clock, and these figures may not reflect the most current PubMed data. Journal fees and open-access listing: DOAJ (CC0, retrieved Sep 16, 2026). Fees paid by institutions: OpenAPC (Open Database License, retrieved Sep 16, 2026). Retractions: Retraction Watch Database via Crossref (retrieved Sep 16, 2026). Journal identifiers and topics: OpenAlex (CC0). Currency conversion: ECB reference rates (Sep 15, 2026). How these numbers are calculated · For organisations.